Given the malleable nature of cancer cells, we should expect, and do see, the development of resistance to any new chemotherapeutic agent. Models that help us understand how this happens are a fi rst step to better and more effective chemotherapeutics. Cancer Discov; 3(1);
In this issue of Cancer Discovery , Jaspers and colleagues ( 1 ) report interesting and provocative results in an ongoing series of investigations aimed at dissecting mechanisms of drug resistance in BRCA-defi cient breast cancer. They use a genetically engineered mouse model (GEMM) lacking both Brca1 and p53 ( K14cre;Brca1 F/F ;p53 F/F ), in which breast cancers arise spontaneously with a mean latency of approximately 213 days ( 2 ) . They have previously shown marked differences in response to chemotherapy in the spontaneously arising tumors, in much the same way responses in tumors in patients vary. In subsequent studies, they transplanted tumors orthotopically into syngeneic wild-type mice, allowing comparisons of therapeutic effi cacy with tumor sampling before and after treatment. Previous studies examined resistance to doxorubicin, paclitaxel, topotecan, cisplatin, and olaparib (AZD2281), with varying results and clinical implications ( 3, 4 ) . The present study proves again the adage that cancer cells are very adaptable. And while many have criticized GEMMs as too narrow and thus too easily treated, the K14cre;Brca1 F/F ;p53 F/F model has elegantly identifi ed several resistance mechanisms. In this issue of Cancer Discovery , we see how cancer cells adapt and develop resistance when fi rstorder mechanisms of tolerance are eliminated. For the fi rst time in an in vivo model, the authors report the development of resistance to inhibitors of PARP by partial restoration of homologous recombination (HR) due to somatic loss of 53BP1 (1 ;p53 F/F model, murine tumors developed olaparib resistance mediated by Pgp, and the resistance could be reversed with the specifi c inhibitor tariquidar ( 3 ). In the study reported here, the investigators probed the model further, inactivating Pgp by breeding the Mdr1a/b -null alleles to homozygosity and isolating resistant tumors. In a subset of tumors, they found resistance mediated by reactivation of HR.
What have we learned? At a very simple level, the data remind us yet again what we have known for decades: the problem is not our drugs, the problem is the intrinsic resistance present at the outset or the acquired tolerance that emerges following drug exposure. Cisplatin, doxorubicin, paclitaxel, and even methotrexate are excellent drugs that can cure, but in a majority of cancers, intrinsic or acquired resistance precludes cure. While some had hoped "targeted therapies" would not suffer this malady, in fact, the data are now overwhelming that resistance is a major problem for these newer therapies. Furthermore, resistance is complex and refractory. For example, a number of mechanisms have been reported to confer resistance to the BRAF inhibitor vemurafenib in clinical samples ( 7 ) . And as the current study shows, resistance is likely just as complex when it comes to PARPi. Previous studies have identifi ed 2 mechanisms of resistance to PARPi in preclinical models and patients: secondary mutations that partially restore BRCA function and overexpression of Pgp ( 3 , 5 ) . To that, we can now add loss of 53BP1 with restoration of HR. Importantly , loss of 53BP1 occurred in only a fraction of the PARP-insensitive tumors, indicating the existence of as-yet additional uncharacterized resistance mechanisms.
As regards our patients, clinical trial data and preclinical models such as the K14cre;Brca1 ;Mdr1a/b −/− model make us confront reality. For women with breast or ovarian cancer in a background of BRCA defi ciency, it seems likely that PARPi will provide a treatment alternative and some benefi t, but for the overwhelming majority inherent and acquired resistance will emerge ( 8, 9 ) . And we may fi nd
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that combinations of PARPi with chemotherapy are also not the answer. These combinations have proven toxic and diffi cult to administer, and there is, at present, no defi nite evidence that such combinations will prove more effective than serial use of the respective agents ( 10 ) . Thus, we should not develop countless PARPi but rather focus on approaches to delay or avert the onset of resistance. Recognizing the role of Pgp in resistance to olaparib, the authors convincingly show that resistance was mitigated and response durability increased with the novel PARP inhibitor AZD2461, a poor Pgp substrate.
Normal metabolism and environmental insults create ongoing DNA damage. PARP1 and the less abundant PARP2 bind single-strand breaks (SSB) in DNA (Figure 1) ( 11 ) . Binding of DNA activates the catalytic C-terminal domain to use the ADP-ribose monomers from NAD + to covalently modify proteins with large linear and branched poly(ADPribose) (PAR) chains as a signal for DNA repair enzymes and scaffolding proteins. After the repair is complete, the PAR chains are degraded. The rapid binding of PARP is critical for repairing DNA SSBs, and when PARP is inhibited, repair is impaired. When these unrepaired SSBs are encountered during DNA replication, the replication fork stalls, converting the SSBs into double-strand breaks (DSB) (Figure 1 ). DSB repair may occur via the more accurate and effi cient HR pathway or by the error prone nonhomologous end joining (NHEJ) pathway. HR requires an orchestrated series of events that includes recognition signaled by γ-H2AX, chromatin remodeling, and DNA repair by BRCA1/2, RAD51, 53BP1, and numerous other proteins. This explains why cancer cells defi cient in BRCA1 and BRCA2, two crucial components of the HR machinery, are hypersensitive to PARPi, a phenomenon sometimes referred to as synthetic lethality.
Although counterintuitive, loss of 53BP1 seemed to promote HR in the BRCA-defi cient cells. Loss of 53BP1 was identifi ed by immunohistochemistry in 3 of 11 olaparib-resistant tumors and in 3 of 12 AZD2461-resistant tumors. Expression loss was explained by truncating mutations, duplications, frame-shifts, and silencing. These observations agree with previous in vitro studies showing that loss of 53BP1 partially restores the HR defect that Brca-1 deletion confers ( 12, 13 ) . How this occurs is not yet understood, but it may be explained by data generated using a dominant negative 53BP1 construct ( 14 ) . These experiments showed that suppression of 53BP1 suppressed NHEJ and increased HRmediated repair, suggesting that 53BP1 may help regulate the choice between NHEJ and HR-mediated repair. Targeting 53BP1 loss to restore sensitivity to a PARPi is theoretically possible, but may prove diffi cult.
We have envisioned the mechanism of action of a PARPi as a simple and straightforward inhibition of PARP activity. But we now know that PARPi, like all good drugs, have complex activity profi les, and this may be good. A recent study has convincingly shown that, like topoisomerase inhibitors, PARPi can act as poisons that trap the PARP1 and PARP2 enzymes on DNA, generating complexes that are more cytotoxic than the unrepaired SSBs caused by PARP inactivation ( 15 ) . Furthermore, the potency in trapping PARP does not correlate with the ability of a PARPi to inhibit PARP catalytic activity and differs markedly among available inhibitors.
Although it is an interesting thesis, this needs to be proven, as resistance mechanisms that restore HR seem indifferent to the "trapped PARPs" that likely continue to form, suggesting such lesions may be tolerable. But if proven to be crucial, then as we understand which property is more important in cytotoxicity and which has greater effect on normal cells and possibly contributes to the poor tolerability of combinations, we may more rationally discriminate among existing PARPi.
As we look back on this decade of targeted therapies, we see therapies that have been thwarted by very adaptable cancer cells using alternate paths to the same end or exploiting redundancy ( 16 ) . With imatinib, mutations that rendered BCR-ABL insensitive to drug allowed reactivation of a critical pathway. With agents targeting VEGF, the data indicate that alternate pathways emerge to drive angiogenesis. And in the case of BRAF inhibitors, multiple adaptations reconstitute signaling through the mitogen-activated protein kinase (MAPK) pathway. But in the case of PARP inhibition, the data, to date, show either exclusion of the drug by an effl ux pump or reactivation of HR as mechanisms of tolerance. Surprisingly, a "work around" PARP has not been seen yet-the alternate pathway seems to be to work around BRCA. If this means cancer cells fi nd it more diffi cult to adapt when PARP is inhibited, then we do well to continue pursuit of PARP as a target.
